Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -4.29% is 91% above its 5-year average of -49.61%, near the high end of its 5-year range (-88.03%–-0.97%).
42.30% above its 12-month average of -7.44%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.60%.
RETURN ON ASSETS (ROA)
-4.29%
RETURN ON ASSETS (ROA) AVG TTM
-7.44%
RETURN ON ASSETS (ROA) AVG 3Y
-40.66%
RETURN ON ASSETS (ROA) AVG 5Y
-49.61%
RETURN ON ASSETS (ROA) AVG 10Y
-53.90%
RETURN ON ASSETS (ROA) AVG 15Y
-62.70%
RETURN ON ASSETS (ROA) AVG 20Y
-67.22%
CURRENT VS TTM AVG
+42.30%
CURRENT VS 3Y AVG
+89.45%
CURRENT VS 5Y AVG
+91.35%
CURRENT VS 10Y AVG
+92.04%
CURRENT VS 15Y AVG
+93.16%
CURRENT VS 20Y AVG
+93.62%
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
+83.72%
vs the sector median at left
Fennec Pharmaceuticals Inc.
Market Cap
$368.91M
Return on Assets (ROA)
-4.29%
TTM Avg
-7.44%
3Y Avg
-40.66%
5Y Avg
-49.61%
Market Cap
$366.39M
Return on Assets (ROA)
-21.30%
TTM Avg
-29.99%
3Y Avg
-30.23%
5Y Avg
-24.37%
Market Cap
$373.40M
Return on Assets (ROA)
-24.06%
TTM Avg
-44.34%
3Y Avg
-68.40%
5Y Avg
-50.78%
Market Cap
$363.54M
Return on Assets (ROA)
53.28%
TTM Avg
-50.19%
3Y Avg
-57.97%
5Y Avg
-53.56%
Market Cap
$361.64M
Return on Assets (ROA)
-115.75%
TTM Avg
-127.38%
3Y Avg
-59.19%
5Y Avg
-98.90%
Market Cap
$384.23M
Return on Assets (ROA)
-69.44%
TTM Avg
-48.37%
3Y Avg
-55.05%
5Y Avg
-50.20%
Market Cap
$348.85M
Return on Assets (ROA)
6.92%
TTM Avg
7.42%
3Y Avg
10.30%
5Y Avg
25.30%
Market Cap
$348.59M
Return on Assets (ROA)
-24.64%
TTM Avg
-45.98%
3Y Avg
-40.55%
5Y Avg
-44.33%
Market Cap
$345.48M
Return on Assets (ROA)
-39.85%
TTM Avg
-37.20%
3Y Avg
-38.95%
5Y Avg
-33.46%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | $368.91M | -4.29% | -7.44% | -40.66% | -49.61% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -21.30% | -29.99% | -30.23% | -24.37% |
| Canopy Growth Corporation (CGC)vs › | $373.40M | -24.06% | -44.34% | -68.40% | -50.78% |
| Agenus Inc. (AGEN)vs › | $363.54M | 53.28% | -50.19% | -57.97% | -53.56% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | -115.75% | -127.38% | -59.19% | -98.90% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $384.23M | -69.44% | -48.37% | -55.05% | -50.20% |
| Embecta Corp. (EMBC)vs › | $348.85M | 6.92% | 7.42% | 10.30% | 25.30% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -24.64% | -45.98% | -40.55% | -44.33% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -39.85% | -37.20% | -38.95% | -33.46% |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | -70.63% | -82.15% | -59.06% | -50.33% |
ROA
-4.3%
ROE
-7.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -13.90% |
| 2024-12-31 | -0.97% |
| 2023-12-31 | -59.73% |
| 2022-12-31 | -88.03% |
| 2021-12-31 | -77.39% |
| 2020-12-31 | -57.64% |
| 2019-12-31 | -92.41% |
| 2018-12-31 | -43.08% |
| 2017-12-31 | -24.81% |
| 2016-12-31 | -70.22% |
| 2015-12-31 | -64.67% |
| 2014-12-31 | -91.74% |
| 2013-12-31 | 105.31% |
| 2012-12-31 | -218.31% |
| 2011-12-31 | 87.55% |
| 2010-12-31 | -130.54% |
| 2009-12-31 | -361.58% |
| 2008-12-31 | -224.42% |
| 2007-12-31 | -77.62% |
| 2006-12-31 | -115.19% |
| 2005-12-31 | -67.66% |
| 2004-06-30 | -20.93% |
| 2003-06-30 | -23.96% |
| 2002-06-30 | -54.57% |
| 2001-06-30 | -23.48% |
| 2000-06-30 | -381.64% |
